What You Should Know:
– Validose, a 10XBeta Venture Studio portfolio company pioneering precision medication delivery, announced today the successful close of a $2 million pre-seed funding round.
– The round was led by Peter Bauer’s Family Office as part of its Technology for Humanity strategy, 10XBeta, and Interstate Fusion Ventures; several angel investors participated.
Validose Revolutionizes Medication Adherence and Precision Dosing
Validose, a healthcare technology company and 10XBeta portfolio member, is transforming medication adherence and precision dosing through advanced engineering solutions. By ensuring secure, real-time dosing and patient engagement, Validose enhances outcomes in clinical trials and therapeutic care.
Addressing one of the most persistent challenges in drug development—patient non-adherence—Validose integrates behavior modeling with remote data capture. The latest funding round will support the finalization of its ophthalmic solution, a smart-dose eye-dropper, set for launch in Q2 2025.
The Validose platform employs an agile dose device, delivering real-time data to clinicians while leveraging behavioral prompts to drive patient adherence. Designed for diverse therapies, the platform includes:
· Ophthalmic Smart-Dose Solution: Ensures precise eye-drop delivery and adherence tracking.
· CNS-Focused Nasal Spray Device & Pill Delivery System: Expands the platform’s reach to additional therapeutic applications.
· Dose Exoskeleton: A multi-sensor, adaptable attachment tracking adherence across various medication forms, including nasal sprays and ophthalmic drops.
By addressing non-adherence—a factor in the failure of 30% of clinical trials—Validose aims to significantly improve trial outcomes and reduce inefficiencies in drug discovery. The solution is particularly critical in high-stakes trials where non-adherence poses significant risks and patient recruitment remains challenging.
“Validose is tackling a major barrier in drug development: clinical trial failures due to patient non-adherence,” said Paul McGrath, CEO of Validose. “Non-adherence increases costs and delays innovation. While existing solutions rely on delayed or passive monitoring, Validose introduces a proactive, real-time adherence platform that reshapes patient behavior, enhances trial oversight, and accelerates decision-making. We appreciate our investors’ support as we work to transform clinical trials and improve drug development.”
Validose’s approach diverges from the current market standard, where adherence is often inconsistently tracked. Traditional methods, such as patient journals or tracking apps, result in unreliable reporting. In contrast, Validose seamlessly integrates with standard drug packaging, providing personalized engagement tools and delivering actionable insights to trial coordinators for timely interventions.
Key components of the Validose platform include:
· Patient Portal: Offers personalized dose reminders, real-time messaging, and behavioral coaching to enhance compliance.
· Clinician Dashboard: Provides real-time adherence insights, enabling trial coordinators to make timely interventions and optimize trial outcomes through secure, immediate access to patient data.
By combining real-time adherence tracking with behavioral engagement, Validose is setting a new standard in medication adherence, clinical trial oversight, and precision dosing, ultimately driving greater efficiency and success in drug development.
